Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Department of Medicine, Universitat Autonoma, Barcelona, Spain.
Internal Medicine Department, Althaia Healthcare Network of Manresa, Rheumatology Unit, Barcelona, Spain.
Med Clin (Barc). 2018 Sep 21;151(6):215-222. doi: 10.1016/j.medcli.2017.11.017. Epub 2017 Dec 20.
To compare clinical, laboratory, treatment and live birth rate data between women with aPL-related obstetric complications (OMAPS) not fulfilling the Sydney criteria and women fulfilling them (OAPS).
Retrospective and prospective multicentre study. Data comparison between groups from The European Registry on Antiphospholipid Syndrome included within the framework of the European Forum on Antiphospholipid Antibody projects.
338 women were analysed: 247 fulfilled the Sydney criteria (OAPS group) and 91 did not (OMAPS group). In the OMAPS group, 24/91 (26.37%) fulfilled laboratory Sydney criteria (subgroup A) and 67/91 (74.63%) had a low titre and/or non-persistent aPL-positivity (subgroup B). Overall, aPL laboratory categories in OAPS vs. OMAPS showed significant differences: 34% vs. 11% (p<0.0001) for category I, 66% vs. 89% (p<0.0001) for category II. No differences were observed when current obstetric complications were compared (p=0.481). 86.20% of OAPS women were treated vs. 75.82% of OMAPS (p=0.0224), particularly regarding the LDA+LMWH schedule (p=0.006). No differences between groups were observed in live births, gestational, puerperal arterial and/or venous thrombosis.
Significant differences were found among aPL categories between groups. Treatment rates were higher in OAPS. Both OAPS and OMAPS groups had similarly good foetal-maternal outcomes when treated. The proposal to modify OAPS classification criteria, mostly laboratory requirements, is reinforced by these results.
比较不满足悉尼标准的抗磷脂抗体相关产科并发症(OMAPS)和满足悉尼标准的抗磷脂抗体相关产科并发症(OAPS)的临床、实验室、治疗和活产率数据。
回顾性和前瞻性多中心研究。在欧洲抗磷脂抗体项目的欧洲论坛框架内,纳入了欧洲抗磷脂综合征注册处的数据比较。
共分析了 338 名女性:247 名符合悉尼标准(OAPS 组),91 名不符合(OMAPS 组)。在 OMAPS 组中,24/91(26.37%)符合实验室悉尼标准(亚组 A),67/91(74.63%)为低滴度和/或非持续抗磷脂抗体阳性(亚组 B)。总体而言,OAPS 与 OMAPS 的抗磷脂实验室分类存在显著差异:I 类 34% vs. 11%(p<0.0001),II 类 66% vs. 89%(p<0.0001)。当比较当前产科并发症时,没有观察到差异(p=0.481)。86.20%的 OAPS 女性接受了治疗,而 75.82%的 OMAPS 女性接受了治疗(p=0.0224),尤其是在 LDA+LMWH 方案中(p=0.006)。两组之间的活产率、妊娠期、产褥期动脉和/或静脉血栓形成无差异。
两组之间的抗磷脂抗体分类存在显著差异。OAPS 组的治疗率更高。治疗后,OAPS 和 OMAPS 两组的母婴结局均良好。这些结果强化了修改 OAPS 分类标准的建议,主要是实验室要求。